Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Sarcoplasmic reticulum-associated cAMP phosphodiesterase activity was examined in microsomes prepared from the left ventricular myocardium of eight heart transplant recipients with end-stage idiopathic dilated cardiomyopathy and six unmatched organ donors with normal cardiac function. At cAMP concentrations less than or equal to 1.0 microM, sarcoplasmic reticulum-associated cAMP phosphodiesterase activity was functionally homogeneous. cAMP phosphodiesterase activity was inhibited competitively by cGMP (Ki = 0.031 +/- 0.008 microM) and the cilostamide derivative OPC 3911 (Ki = 0.018 +/- 0.004 microM), but was essentially insensitive to rolipram. Vmax and Km were 781.7 +/- 109.2 nmol/mg per min and 0.188 +/- 0.031 microM, respectively, in microsomes prepared from nonfailing hearts and 793.9 +/- 68.9 nmol/mg per min and 0.150 +/- 0.027 microM in microsomes prepared from failing hearts. Microsomes prepared from nonfailing and failing hearts did not differ with respect to either the ratio of cAMP phosphodiesterase activity to ATP-dependent Ca2+ accumulation activity or the sensitivity of cAMP phosphodiesterase activity to inhibition by OPC 3911. These data suggest that the diminished inotropic efficacy of phosphodiesterase inhibitors in failing human hearts does not result from changes in the level, kinetic properties, or pharmacologic sensitivity of sarcoplasmic reticulum-associated cAMP phosphodiesterase activity.

[1]  J. H. Wang,et al.  Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts. , 1990, The Journal of clinical investigation.

[2]  Masa-aki Ito,et al.  Effects of Amrinone and Enoximone on the Subclasses of Cyclic AMP Phosphodiesterase from Human Heart and Kidney , 1990, Journal of cardiovascular pharmacology.

[3]  E. Degerman,et al.  Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Bristow,et al.  Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. , 1989, Circulation research.

[5]  R. Bentley,et al.  Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. , 1989, Journal of cardiovascular pharmacology.

[6]  J. Port,et al.  Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. , 1989, Molecular pharmacology.

[7]  M. Böhm,et al.  Subsensitivity of the Failing Human Heart to Isoprenaline and Milrinoneo is Related to β‐Adrenoceptor Downregulation , 1988, Journal of cardiovascular pharmacology.

[8]  J. Beavo,et al.  Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. , 1988, The Journal of biological chemistry.

[9]  M. Artman,et al.  Subcellular Distribution of High‐Affinity Type IV Cyclic AMP Phosphodiesterase Activity in Rabbit Ventricular Myocardium: Relations to the Effects of Cardiotonic Drugs , 1988, Circulation research.

[10]  Beavo Ja.  Multiple isozymes of cyclic nucleotide phosphodiesterase. , 1988 .

[11]  J. Beavo.  Multiple isozymes of cyclic nucleotide phosphodiesterase. , 1988, Advances in second messenger and phosphoprotein research.

[12]  A. Fabiato,et al.  Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. , 1988, Methods in enzymology.

[13]  R. Kincaid,et al.  Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates. , 1988, Methods in enzymology.

[14]  H. R. Kaplan,et al.  Subclasses of Cyclic AMP‐Specific Phosphodiesterase in Left Ventricular Muscle and Their Involvement in Regulating Myocardial Contractility , 1987, Circulation research.

[15]  F. Schoen,et al.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. , 1987, Circulation.

[16]  P. J. England,et al.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. , 1987, The Biochemical journal.

[17]  D. Robertson,et al.  LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. , 1986, Molecular pharmacology.

[18]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[19]  S. Jamieson,et al.  β1‐ and β2‐Adrenergic‐Receptor Subpopulations in Nonfailing and Failing Human Ventricular Myocardium: Coupling of Both Receptor Subtypes to Muscle Contraction and Selective β1‐Receptor Down‐Regulation in Heart Failure , 1986 .

[20]  J. Beavo,et al.  Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. , 1986, Molecular pharmacology.

[21]  H. R. Kaplan,et al.  Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility. , 1986, Journal of cyclic nucleotide and protein phosphorylation research.

[22]  M. Bristow,et al.  Pharmacology and inotropic potential of forskolin in the human heart. , 1984, The Journal of clinical investigation.

[23]  R. Colman,et al.  Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. , 1984, Biochemistry.

[24]  L. Brunton,et al.  Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. , 1983, The Journal of biological chemistry.

[25]  R. C. Dage,et al.  Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043 , 1982, Journal of cardiovascular pharmacology.

[26]  W. Cleland,et al.  Statistical analysis of enzyme kinetic data. , 2006, Methods in enzymology.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[29]  P. S. Chen,et al.  Microdetermination of Phosphorus , 1956 .